

// ()
//
// , ,

*

, :

, ,

, :

() ()

CCI

$5-7 \times 10 \text{ L/m}^2$ - $10 \times 10 \text{ L/m}^2$

:

, :

, :

HLA

.(-)

.()

HLA

* /L

(%) HLA

%

(%) %

- * /L

.(-)

*

%

$$\times \left(\frac{\quad - \quad}{10^{11} \times} \right) = \text{CCI}$$

 $10^{11} \times$

HLA-DR

* /L

CCI

- - * /L

HLA

% - .()

:

/ ,

/ /

HLA

/ /

/

)

)

(

(

()

-

()	()	
/	/	() •
()	(%)	•
(/)	(/)	%
(/)	()	ALL •
(/)	(%)	AML
(/)	()	•
(/)	()	
/ ± /	/ ± /	•
/ ± /	/ ± /	•
		•
/		•
	/	•

CCI

%

)

(

P < /

)

(

(%) .(P < / P < /)

(% /)

/

()

%

%

.()

% /

%

()

% /

REFERENCES

2. Barz D, Staack D, Lehmann R, Stange K, Schnurstein K. Antibody formation after filtered blood cell replacement in hematologic-oncologic patients. *Beitr Infusionsther Transfusionsmed* 1996; 33: 30-4.
3. Balducci L, Benson K, Lyman GH, Sanderson R, Fields K, Ballester OF, et al. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. *Transfusion* 1993; 33(8): 665-70.
4. Hoffman R. *Hematology: Basic principles and practice*. USA: Churchill Livingstone, 1991.
5. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. *Blood* 1988; 71(5): 1402-7.